Rock Springs Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Rock Springs Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-900,000	Closed	-$4.61M	–	141
2019 Q3	$4.61M	Hold	900,000	–	–	0.18%	107
2019 Q2	$6.44M	Buy	900,000 +185,000	+26%	+$2.09M	0.23%	92
2019 Q1	$9.49M	Buy	715,000 +101,396	+17%	+$1.08M	0.37%	84
2018 Q4	$4.83M	Hold	613,604	–	–	0.23%	97
2018 Q3	$6.8M	Buy	613,604 +33,604	+6%	+$417K	0.25%	101
2018 Q2	$7.78M	Buy	580,000 +90,000	+18%	+$1.13M	0.3%	97
2018 Q1	$6.37M	Buy	490,000 +40,000	+9%	+$497K	0.27%	102
2017 Q4	$4.14M	Hold	450,000	–	–	0.19%	113
2017 Q3	$3.63M	Buy	+450,000	New	+$3.04M	0.17%	113
2015 Q1	–	Sell	-100,000	Closed	-$983K	–	109
2014 Q4	$983K	Sell	100,000 -200,000	-67%	-$1.61M	0.12%	92
2014 Q3	$2.05M	Buy	+300,000	New	+$1.84M	0.32%	75

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rock Springs Capital Management's CBAY Position: Q4 2019 in Review

Rock Springs Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 900,000 shares — an estimated $4.61M sold.

Rock Springs Capital Management first reported a position in CBAY in Q3 2014 and held it in 11 quarters. The position peaked at $9.49M in Q1 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Rock Springs Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
Rock Springs Capital Management sold 900,000 Cymabay Therapeutics shares in Q4 2019, an estimated $4.61M.
Rock Springs Capital Management first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 11 quarters.
Rock Springs Capital Management's Cymabay Therapeutics position peaked at $9.49M in Q1 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.